Investments Detail

Back to Investments

Enabler of Biopharmaceutical collaboration

Vespa Capital acquired BioPhorum in 2018

Business Profile

BioPhorum is a cross industry collaboration group connecting most of the world's largest biopharmaceutical manufacturers and suppliers to solve pertinent pre-competitive industry challenges and improve operational best practices.
BioPhorum creates an environment where biopharmaceutical companies can collaborate for the benefit of all. This is particularly important given the complexities and high costs involved in manufacturing biopharmaceutical drugs.
BioPhorum facilitates seven forums (“Phorums”) across the biopharmaceutical value chain - Drug Substance, Drug Development, Fill Finish, Technology Roadmap, Supply Partner, Information Technology and Cell & Gene Therapy.

Key Strengths

Visit Site

Vespa Capital invested in BioPhorum in June 2018 attracted by its unique collaboration model and virtual office structure and is working in partnership with the team to deliver the next phase of BioPhorum’s development.

Highly experienced management team, with specialist knowledge and deep relationships in their various fields.
Unique collaboration model, utilising technology to engage with members globally, facilitated by experienced pharmaceutical professionals and industry subject matter experts.
Market leading niche business in the high growth biopharmaceutical sector with an international blue chip client base.

Enviable levels of deep engagement with a range of companies operating across the biopharmaceutical value chain, including 23 of the 25 largest biopharmaceutical firms.
Members collaborate to drive development at the cutting edge of biopharmaceutical manufacturing. In 2017 BioPhorum led the production of the global Technology Roadmap for the industry and in 2018 incubated a Phorum to focus on Cell and Gene Therapy drug manufacturing.

What BioPhorum says

When we were looking for an investment partner to help us go to the next stage of our development, we wanted constructive engagement not interference, experience in areas that were new to us and a passion for the life sciences industry that matched our own. In Vespa Capital we found all these things.

Simon Chalk, Director, BioPhorum